Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
4,594 results
- BALATONIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion: primary endpoint results, effect estimate with confidence…
- BALLAD+Independent statistical analysis of A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid: primary endpoint results, effect estimate with…
- Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST: Complete Statistical AnalysisIndependent statistical analysis of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BARIIndependent statistical analysis of Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus: Complete Statistical AnalysisIndependent statistical analysis of Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05188521).
- Barre Exercise in Parkinson’s: Complete Statistical AnalysisIndependent statistical analysis of Barre Exercise in Parkinson's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06203990).
- Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00410059).
- BAY 0 9867 Cipro Pediatric Use Study (QUIP): Complete Statistical AnalysisIndependent statistical analysis of BAY 0 9867 Cipro Pediatric Use Study (QUIP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00761462).
- BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BCAAIndependent statistical analysis of Mechanisms to Reduce Mental and Physical Fatigue Following Exercise Training in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BE ACTIVE 2Independent statistical analysis of A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents: Complete Statistical AnalysisIndependent statistical analysis of Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BE READYIndependent statistical analysis of A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic…
- BE VIVIDIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis: primary…
- BE-SMARTIndependent statistical analysis of Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03183388).
- BEACONIndependent statistical analysis of Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease…
- BEACONIndependent statistical analysis of HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BEACON IIIndependent statistical analysis of Evaluation of Methods for Implementation of a Comfort Care Order Set: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BEAMIndependent statistical analysis of A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin Depressions: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BEe-HIVeIndependent statistical analysis of B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud’s Phenomenon: Complete Statistical AnalysisIndependent statistical analysis of Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BEGIN™Independent statistical analysis of Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01079234).
- BEGSIndependent statistical analysis of Benralizumab for Eosinophilic Gastritis (BEGS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03473977).
- Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01351766).
- Behavioral Economic Treatment to Enhance Rural (BETTER) Living: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Economic Treatment to Enhance Rural (BETTER) Living: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05235971).
- BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: Complete Statistical AnalysisIndependent statistical analysis of BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: primary endpoint…
- Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04676360).
- Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02152345).
- BELLE-4Independent statistical analysis of A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation: primary endpoint results,…
- Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00705250).
- Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Benefit of Assistive Listening Device for Lateralization: Complete Statistical AnalysisIndependent statistical analysis of Benefit of Assistive Listening Device for Lateralization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05072457).
- Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: Complete Statistical AnalysisIndependent statistical analysis of Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Benzocaine Gel Toothache Dose-Response Study: Complete Statistical AnalysisIndependent statistical analysis of Benzocaine Gel Toothache Dose-Response Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00474175).
- Berinert (C1INH) vs Placebo for DGF/IRI: Complete Statistical AnalysisIndependent statistical analysis of Berinert (C1INH) vs Placebo for DGF/IRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04696146).
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BESPOKEIndependent statistical analysis of A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BESTFITIndependent statistical analysis of BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01903265).
- BETAIndependent statistical analysis of Behavioral Economics to Improve Antihypertensive Therapy Adherence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04029883).
- Beta Events and Sensory Perception: Complete Statistical AnalysisIndependent statistical analysis of Beta Events and Sensory Perception: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04062318).
- Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison: Complete Statistical AnalysisIndependent statistical analysis of Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01002456).
- Beta-blockers in Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Beta-blockers in Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02507011).
- BETTERIndependent statistical analysis of Bringing Education Through Technology, Empathic Listening, and Research: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05214118).